Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Baxter International (NYSE:BAX) launched a Phase III pivotal trial of adult stem cell therapy for treating a heart condition called chronic myocardial ischemia.
Patients rushed to the hospital for a heart attack are no better off with a stent than they would be with less-costly drug therapy, according to a new study. Implanting a stent to prop open blocked arteries represents a more costly alternative that failed to improve patient outcomes, according to researchers from the Stony Brook University Medical Center in New York.
Former Stryker (NYSE:SYK) CEO Stephen MacMillan’s departure from the company may have come as the result of an extramarital affair with a former company employee, according to a report in the Wall Street Journal.